APA

Wenzel S., Castro M., Corren J., Maspero J., Wang L., Zhang B., Pirozzi G., Sutherland E. R., Evans R. R., Joish V. N., Eckert L., Graham N. M. H., Stahl N., Yancopoulos G. D., Louis-Tisserand M. & Teper A. (20160801). Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. : Lancet (London, England).

Chicago

Wenzel Sally, Castro Mario, Corren Jonathan, Maspero Jorge, Wang Lin, Zhang Bingzhi, Pirozzi Gianluca, Sutherland E Rand, Evans Robert R, Joish Vijay N, Eckert Laurent, Graham Neil M H, Stahl Neil, Yancopoulos George D, Louis-Tisserand Mariana and Teper Ariel. 20160801. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. : Lancet (London, England).

Harvard

Wenzel S., Castro M., Corren J., Maspero J., Wang L., Zhang B., Pirozzi G., Sutherland E. R., Evans R. R., Joish V. N., Eckert L., Graham N. M. H., Stahl N., Yancopoulos G. D., Louis-Tisserand M. and Teper A. (20160801). Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. : Lancet (London, England).

MLA

Wenzel Sally, Castro Mario, Corren Jonathan, Maspero Jorge, Wang Lin, Zhang Bingzhi, Pirozzi Gianluca, Sutherland E Rand, Evans Robert R, Joish Vijay N, Eckert Laurent, Graham Neil M H, Stahl Neil, Yancopoulos George D, Louis-Tisserand Mariana and Teper Ariel. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. : Lancet (London, England). 20160801.